Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: A multicenter, randomized, double-blind, parallel-group, placebo controlled trial

PLoS ONE

Volumn 9, Issue 4, 2014, Pages

  Kim, Sin Gon ^a   Kim, Doo Man ^b   Woo, Jeong Taek ^c   Jang, Hak Chul ^d   Chung, Choon Hee ^e   Ko, Kyung Soo ^f   Park, Jeong Hyun ^f   Park, Yong Soo ^g   Kim, Sang Jin ^h   Choi, Dong Seop ^a  

^a Korea University College of Medicine   (South Korea)

^b Hallym University   (South Korea)

^c Kyung Hee University College of Medicine   (South Korea)

^d Seoul National University Bundang Hospital   (South Korea)

^e Wonju Severance Christian Hospital   (South Korea)

^f Inje University College of Medicine   (South Korea)

^g Hanyang University Guri Hospital   (South Korea)

^h Soonchunhyang University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN B; FATTY ACID; GLYCOSYLATED HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOBEGLITAZONE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; TRIACYLGLYCEROL; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; LIPID; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FATTY ACID BLOOD LEVEL; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN; BLOOD; CLINICAL TRIAL; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; TIME; TREATMENT OUTCOME;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; PYRIMIDINES; THIAZOLIDINEDIONES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84899693223     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092843     Document Type: Article

References (18)

1. Yki-Jarvinen H (2004) Thiazolidinediones. N Engl J Med 351: 1106-1118.
2. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, et al. (2006) Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 2427-2443.
3. Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, et al. (2007) Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemia. Diabetes Care 30: 2458-2464.
4. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, et al. (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366: 1279-1289.
5. Cariou B, Charbonnel B, Staels B (2012) Thiazolidinediones and PPARgamma agonists: time for a reassessment. Trends Endocrinol Metab 23: 205-215.
6. Nissen SE, Wolski K (2010) Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality. Arch Intern Med 170: 1191-1201.
7. Neumann A, Weill A, Ricordeau P, Fagot JP, Alla F, et al. (2012) Pioglitazone and risk of bladder cancer among diabetic patients in France: a populationbased cohort study. Diabetologia 55: 1953-1962.
8. Jones D (2010) Potential remains for PPAR-targeted drugs. Nat Rev Drug Discov 9: 668-669.
9. Kim BY, Ahn JB, Lee HW, Kang SK, Lee JH, et al. (2004) Synthesis and biological activity of novel substituted pyridines and purines containing 2,4-thiazolidinedione. Eur J Med Chem 39: 433-447.
10. Lee HW, Kim BY, Ahn JB, Kang SK, Lee JH, et al. (2005) Molecular design, synthesis, and hypoglycemic and hypolipidemic activities of novel pyrimidine derivatives having thiazolidinedione. Eur J Med Chem 40: 862-874.
11. Kim JW, Kim JR, Yi S, Shin HS, Yoon SH, et al. (2011) Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferatoractivated receptor-gamma agonist: a single-and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Clin Ther 33: 1819-1830.
12. Shin D, Kim TE, Yoon SH, Cho JY, Shin SG, et al. (2012) Assessment of the pharmacokinetics of co-administered metformin and lobeglitazone, a thiazolidinedione antihyperglycemic agent, in healthy subjects. Curr Med Res Opin 28: 1213-1220.
13. Aronoff S, Rosenblatt S, Braithwaite S, Egan JW, Mathisen AL, et al. (2000) Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebocontrolled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23: 1605-1611.
14. Majima T, Komatsu Y, Doi K, Shigemoto M, Takagi C, et al. (2006) Safety and efficacy of low-dose pioglitazone (7.5 mg/day) vs. standard-dose pioglitazone (15 mg/day) in Japanese women with type 2 diabetes mellitus. Endocr J 53: 325-330.
15. Haffner SM (1998) Dyslipidemia management in adults with diabetes. Diabetes Care 27 Suppl 1: S68-71.
16. Nissen SE, Wolski K, Topol EJ (2005) Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. JAMA 294: 2581-2586.
17. Wilding JP, Gause-Nilsson I, Persson A (2007) Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. Diab Vasc Dis Res 4: 194-203.
18. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B (2007) Safety issues and prospects for future generations of PPAR modulators. Biochim Biophys Acta 1771: 1065-1081